These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 717886)

  • 1. Electronic cell volume analysis of growth and rejection of EL-4 ascites tumor cells.
    Zucker RM; Harari J; Finley J; Kambour M
    Am J Vet Res; 1978 Oct; 39(10):1710-2. PubMed ID: 717886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
    Yoshida R; Yoneda Y; Kuriyama M; Kubota T
    J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
    Rakhmilevich AL
    Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute rejection of interferon-treated leukemia cells injected into lethally irradiated syngeneic mice.
    Neri M; Zei T; Tentori L; Bonmassar E; Affabris E; Iorio AM
    Nat Immun; 1993; 12(6):302-15. PubMed ID: 7505668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
    Nagarkatti M; Kaplan AM
    J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid resistance to the ascites form of the murine sarcoma.
    Płytycz B; Seljelid R
    Arch Immunol Ther Exp (Warsz); 1987; 35(6):863-9. PubMed ID: 3508043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
    Dennert G; Anderson CG; Warner J
    J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
    Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
    J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration.
    Schick B; Berke B
    Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis and growth of Friend tumor cells in irradiated syngeneic hosts.
    Matioli G
    J Reticuloendothel Soc; 1974 Apr; 15(4):282-96. PubMed ID: 4838059
    [No Abstract]   [Full Text] [Related]  

  • 13. Lectin-dependent cell-mediated cytotoxicity: assessment of cytotoxic reactivity following challenge with syngeneic tumors.
    Laux DC; Parker BM; DiSciullo SO; Petrarca MA; McAllister CG
    J Natl Cancer Inst; 1984 Mar; 72(3):667-72. PubMed ID: 6583449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of allogeneic stimulation and exogenous interleukin for syngeneic tumor rejection.
    Sherburne CG; Condie RM; Nnadi EC; Adlin M
    Transplant Proc; 1987 Feb; 19(1 Pt 1):628-31. PubMed ID: 3493564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor induction by immunologically activated murine leukemia virus: cellular immunity early in the graft-vs-host reaction.
    Ruddle NH; Armstrong MY; Richards FF
    J Immunol; 1974 Feb; 112(2):706-15. PubMed ID: 4149884
    [No Abstract]   [Full Text] [Related]  

  • 18. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
    McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
    Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.